GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SciSparc Ltd (OTCPK:SPRCY) » Definitions » COGS-to-Revenue

SciSparc (SciSparc) COGS-to-Revenue : -0.64 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is SciSparc COGS-to-Revenue?

SciSparc's Cost of Goods Sold for the six months ended in Dec. 2023 was $-0.58 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.91 Mil.

SciSparc's COGS to Revenue for the six months ended in Dec. 2023 was -0.64.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SciSparc's Gross Margin % for the six months ended in Dec. 2023 was 164.39%.


SciSparc COGS-to-Revenue Historical Data

The historical data trend for SciSparc's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciSparc COGS-to-Revenue Chart

SciSparc Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.24 0.24

SciSparc Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.24 0.64 -0.64

SciSparc COGS-to-Revenue Calculation

SciSparc's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.683 / 2.879
=0.24

SciSparc's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=-0.584 / 0.907
=-0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciSparc  (OTCPK:SPRCY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SciSparc's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - -0.584 / 0.907
=164.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


SciSparc COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of SciSparc's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SciSparc (SciSparc) Business Description

Traded in Other Exchanges
Address
20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority.